The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer
Open accessPublished version of a preprint
Abstract
Preclinical evidence suggests that concomitant BRAF and EGFR inhibition leads to sustained suppression of MAPK signaling and suppressed tumor growth in BRAFV600E colorectal cancer models. Patients with refractory BRAFV600-mutant metastatic CRC (mCRC) were treated with a selective RAF kinase inhibitor (encorafenib) plus a monoclonal antibody targeting EGFR (cetuximab), with (n = 28) or without (n = 26) a PI3Kα inhibitor (alpelisib). The primary objective was to determine the maximum tolerated dose (MTD) or a recommended phase II dose. Dose-limiting toxicities were reported in 3 patients receiving dual treatment and 2 patients receiving triple treatment. The MTD was not reached for either group and the phase II doses were selected as 200 mg encorafenib (both groups) and 300 mg alpelisib. Combinations of cetuximab and encorafenib showed promising clinical activity and tolerability in patients with BRAF-mutant mCRC; confirmed overall response rates of 19% and 18% were observed and median progression-free survival was 3.7 and 4.2 months for the dual- and triple-therapy groups, respectively. Significance: Herein, we demonstrate that dual- (encorafenib plus cetuximab) and triple- (encorafenib plus cetuximab and alpelisib) combination treatments are tolerable and provide promising clinical activity in the difficult-to-treat patient population with BRAF-mutant mCRC. Cancer Discov; 7(6); 610–9. ©2017 AACR. See related commentary by Sundar et al., p. 558. This article is highlighted in the In This Issue feature, p. 539
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent clinical trials report that combined BRAF and EGFR inhibition significantly improves response rates in BRAF (V600E) metastatic CRC patients (10% or 19%) [10, 13], and has now become the FDA-approved, standard of care.”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Combined EGFR and BRAF blockade proved synthetic lethality in preclinical models of BRAFV600E CRC and modestly improves survival of patients with advanced disease [7, 8, 15–17].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Indeed, in BRAFV600 colorectal cancer, targeting EGFR—the RTK thought to be the primary driver of feedback reactivation from preclinical studies—in combination with BRAF inhibition, has led to an improvement in clinical efficacy (34–39).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [35]
In the citing paper
“However, two clinical trials showed that adding PI3K inhibitors to cetuximab did not improve PFS, ORR and OS in mCRC patients [68,69].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,858
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citationDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,918
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Self-citationRAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
Flagged first, then by citations
Research works printed but not linked: 1
- Zelboraf, 2012, Summary of Product Characteristics
Cited by
Sorted by citations
Items 101–200 of 232
Ye, L.-F., Huang, Z.-Y., Chen, X., Chen, Z., Wu, S., Ren, C., Hu, M.-T., Bao, H., Jin, Y., Wang, F., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100883 · Cited by 26
Wang, S., Cheng, L., Wu, H., & Li, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.949656 · Cited by 25
Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09344-3 · Cited by 22
“Recent clinical trials report that combined BRAF and EGFR inhibition significantly improves response rates in BRAF (V600E) metastatic CRC patients (10% or 19%) [10, 13], and has now become the FDA-approved, standard of care.”
BackgroundTargeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies
Sundar, R., Hong, D. S., Kopetz, S., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0087 · Cited by 24
Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects
Lam, M., Lum, C., Latham, S., Smith, S. T., Prenen, H., & Segelov, E. (2020) · Cancer Management and Research · doi:10.2147/cmar.s213236 · Cited by 26
Randon, G., Intini, R., Cremolini, C., Elez, E., Overman, M. J., Lee, J., Manca, P., Bergamo, F., Pagani, F., Antista, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.018 · Cited by 24
Ye, Y., Huang, Z., Zhang, M., Li, J., Zhang, Y., & Lou, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114183 · Cited by 27
BRAF-mutant colorectal cancer, a different breed evolving
Lai, E., Pretta, A., Impera, V., Mariani, S., Giampieri, R., Casula, L., Pusceddu, V., Coni, P., Fanni, D., Puzzoni, M., et al. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1470928 · Cited by 25
Chu, X., Bu, Y., & Yang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.785855 · Cited by 24
Colorectal cancer genomics and designing rational trials
Mondaca, S., & Yaeger, R. D. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.27 · Cited by 22
Self-citationEbi, H., Bando, H., Taniguchi, H., Sunakawa, Y., Okugawa, Y., Hatanaka, Y., Hosoda, W., Kumamoto, K., Nakatani, K., & Yamazaki, K. (2020) · Cancer Science · doi:10.1111/cas.14567 · Cited by 23
Whitehead, C. E., Ziemke, E. K., Frankowski-McGregor, C. L., Mumby, R. A., Chung, J., Li, J., Osher, N., Coker, O., Baladandayuthapani, V., Kopetz, S., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00781-6 · Cited by 27
Prognostic and predictive molecular biomarkers in colorectal cancer
Zhang, J., Zhu, H., Liu, W., Miao, J., Mao, Y., & Li, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1532924 · Cited by 24
Ros, J., Baraibar, I., Martini, G., Salvà, F., Gonzalez, N. S., Cuadra‐Urteaga, J. L., Dienstmann, R., Tabernero, J. M., & Élez, E. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00913-5 · Cited by 22
Self-citationTargeting BRAF V600E in metastatic colorectal cancer: where are we today?
Motta, R., Arnao, V. Y., Ballena, S. V. L., Macha, C. A., Lezama, M. S., Román, C. P., Beltran, P. M., & Torrejon, A. F. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.1489 · Cited by 23
Dankner, M. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00195 · Cited by 23
Huijberts, S. C. F. A., van Geel, R. M. J. M., Bernards, R., Beijnen, J. H., & Steeghs, N. (2020) · Future Oncology · doi:10.2217/fon-2019-0748 · Cited by 23
Guerrero, P., Albarrán, V., San Román, M., González-Merino, C., García de Quevedo, C., Moreno, J., Calvo, J. C., González, G., Orejana, I., Chamorro, J., et al. (2023) · Cancers · doi:10.3390/cancers15215243 · Cited by 21
Cardiovascular toxicity of PI3Kα inhibitors
Sadasivan, C., Zhabyeyev, P., Labib, D., White, J. A., Paterson, D. I., & Oudit, G. Y. (2020) · Clinical Science · doi:10.1042/cs20200302 · Cited by 22
A systematic review and meta-analysis of selected toxicity endpoints of alpelisib
Shields, M. D., Mo, Q., Armitage, M., Sharpe, S. C., & Costa, R. L. B. (2020) · Oncotarget · doi:10.18632/oncotarget.27770 · Cited by 21
Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead?
Capogiri, M., Micheli, A. J. D., Lassaletta, Á., Muñoz, D. P., Coppé, J., Mueller, S., & Stücklin, A. G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1074726 · Cited by 21
Ross, K. C., Chin, K. F., Kim, D., Marion, C. D., Yen, T. J., & Bhattacharjee, V. (2018) · Oncotarget · doi:10.18632/oncotarget.24341 · Cited by 20
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives
Personeni, N., Smiroldo, V., Giunta, E. F., Prete, M. G., Rimassa, L., Bregni, G., & Sclafani, F. (2021) · Cancers · doi:10.3390/cancers13184506 · Cited by 19
Cremolini, C., Pietrantonio, F., Tomasello, G., Dadduzio, V., Moretto, R., Morano, F., Schirripa, M., Antoniotti, C., Fucà, G., Bergamo, F., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000241 · Cited by 19
Arcucci, S., Ramos-Delgado, F., Cayron, C., Therville, N., Gratacap, M., Basset, C., Thibault, B., & Guillermet-Guibert, J. (2021) · Biochemical Journal · doi:10.1042/bcj20210004 · Cited by 15
Napolitano, S., Ciardiello, D., Cioli, E., Martinelli, E., Troiani, T., Zampino, M. G., Fazio, N., Vita, F. D., Ciardiello, F., & Martini, G. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102905 · Cited by 19
SIRT1: a novel regulator in colorectal cancer
Dong, W., Lu, J., Li, Y., Zeng, J., Du, X., Yu, A., Zhao, X., Chi, F., Xi, Z., & Cao, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117176 · Cited by 19
Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer
Fernandes, M. S., Sanches, J., & Seruca, R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_4 · Cited by 18
Zhabyeyev, P., McLean, B. A., Chen, X., Vanhaesebroeck, B., & Oudit, G. Y. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.05.008 · Cited by 18
The Role of BRAF in Metastatic Colorectal Carcinoma–Past, Present, and Future
Djanani, A. M., Eller, S., Öfner, D., Troppmair, J., & Maglione, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239001 · Cited by 18
Patel, N., Chong, A. T., Kolla, A. M., Mabud, T. S., Kulkarni, K., Masrouha, K. Z., Taslakian, B., & Bertino, F. J. (2022) · Seminars in Interventional Radiology · doi:10.1055/s-0042-1757940 · Cited by 17
Giordano, G., Parcesepe, P., Bruno, G., Piscazzi, A., Lizzi, V., Remo, A., Pancione, M., D'Andrea, M. R., Santis, E. D., Coppola, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147717 · Cited by 19
PI3Kα in cardioprotection: Cytoskeleton, late Na+ current, and mechanism of arrhythmias
Zhabyeyev, P., Chen, X., Vanhaesebroeck, B., & Oudit, G. (2019) · Channels · doi:10.1080/19336950.2019.1697127 · Cited by 18
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)
García‐Albéniz, X., Alonso, V., Escudero, P., Méndez, M., Gallego-Plazas, J., Rodríguez, J. R., Salud, A., Fernández-Plana, J., Manzano, H., Zanui, M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0728 · Cited by 16
Colorectal cancer: Review of signaling pathways and associated therapeutic strategies
Leiphrakpam, P. D., Rajappa, S. J., Krishnan, M., Batra, R., Murthy, S. S., & Are, C. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27295 · Cited by 17
Trullas, A., Delgado, J., Koenig, J., Fuerstenau, U., Dedorath, J., Hausmann, S., Stock, T., Enzmann, H. G., & Pignatti, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100031 · Cited by 16
Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer
Johnson, B., & Kopetz, S. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00747-5 · Cited by 14
Alpelisib and radiotherapy treatment enhances Alisertib-mediated cervical cancer tumor killing.
Tayyar, Y., Idris, A., Vidimce, J., Ferreira, D. A., & McMillan, N. A. J. (2021) · PubMed Central · Cited by 14
Sun, Z., Shi, M., Xia, J., Li, X., Chen, N., Wang, H., Gao, Z., Jia, J., Peng, Y., Ji, D., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010460 · Cited by 13
Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer
Meneguzzo, A., Lazzarotto, A., & Alaibac, M. (2019) · In Vivo · doi:10.21873/invivo.11793 · Cited by 13
Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy
Rosati, G., Aprile, G., Colombo, A., Cordio, S. S., Giampaglia, M., Cappetta, A., Porretto, C. M., Stefano, A. D., Bilancia, D., & Avallone, A. (2022) · Biomedicines · doi:10.3390/biomedicines10051035 · Cited by 14
Gu, R., Fang, H., Wang, R., Dai, W., & Cai, G. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1764 · Cited by 14
Matsuoka, T., & Yashiro, M. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i5.366 · Cited by 13
Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
Ros, J., Gonzalez, N. S., Baraibar, I., Salvà, F., Tabernero, J. M., & Élez, E. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221110644 · Cited by 12
Self-citationInsights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis
Rezaeian, A.-H., Inuzuka, H., & Wei, W. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.009 · Cited by 12
Pharmacokinetics and Pharmacodynamic of Alpelisib
Royer, B., Kaderbhaï, C., & Schmitt, A. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01195-2 · Cited by 12
Baraibar, I., Ros, J., Mulet-Margalef, N., Salvà, F., Argilés, G., Martini, G., Cuadra‐Urteaga, J. L., Sardo, E., Ciardiello, D., Tabernero, J. M., et al. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1782194 · Cited by 13
Self-citationLi, S., Hu, H., Ding, D., Zhu, Y., & Huang, J. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01627-8 · Cited by 13
Drug Development in Tissue-Agnostic Indications
du Rusquec, P., & Tourneau, C. L. (2021) · Cancers · doi:10.3390/cancers13112758 · Cited by 12
Rodriquenz, M. G., Ciardiello, D., Latiano, T. P., Maiorano, B. A., Martinelli, E., Silvestris, N., Ciardiello, F., & Maiello, E. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103657 · Cited by 12
Takeda, H., & Sunakawa, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.602194 · Cited by 11
Yamazaki, K., Taniguchi, H., Yoshino, T., Akagi, K., Ishida, H., Ebi, H., Nakatani, K., Muro, K., Yatabe, Y., Yamaguchi, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13617 · Cited by 11
Self-citationApplication of histology-agnostic treatments in metastatic colorectal cancer
Bianchi, A. S., Agostara, A. G., Patelli, G., Mauri, G., Pizzutilo, E. G., & Siena, S. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.05.013 · Cited by 12
Importance of genetic screens in precision oncology
Mulero‐Sánchez, A., Pogacar, Z., & Vecchione, L. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000505 · Cited by 12
Lim, A. R., Kim, B., Kim, J. H., Hyun, M. H., Park, K. H., Kim, Y. H., & Lee, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1390452 · Cited by 10
Piercey, O., Tie, J., Hollande, F., Wong, H., Mariadason, J. M., & Desai, J. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.04.004 · Cited by 11
Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations
Kanat, Ö., Ertaş, H., & Caner, B. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i10.1080 · Cited by 11
Advances on the BRAF Front in Colorectal Cancer
Jankú, F. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0125 · Cited by 10
The Genomic Environment of BRAF Mutated and BRAF/PIK3CA Double Mutated Colorectal Cancers
Voutsadakis, I. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175132 · Cited by 10
Kollipara, S., Ahmed, T., & Sivadasu, P. (2023) · Xenobiotica · doi:10.1080/00498254.2023.2250856 · Cited by 12
Wang, P.-P., Lin, C., Wang, J., Margonis, G. A., & Wu, B. (2022) · Cancers · doi:10.3390/cancers14174067 · Cited by 10
Dazio, G., Epistolio, S., Frattini, M., & Saletti, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247523 · Cited by 10
Tak, E., An, H., Lee, A. S., Han, K., Choi, J., Kim, H., Hong, Y. S., Kim, S., Choi, E. K., Kim, J. E., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04005-3 · Cited by 9
Piringer, G., Decker, J., Trommet, V., Kühr, T., Heibl, S., Dörfler, K., & Thaler, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1166545 · Cited by 10
Insights into the FDA 2018 New Drug Approvals
Bedair, A., & Mansour, F. R. (2019) · Current Drug Discovery Technologies · doi:10.2174/1570163816666191202104315 · Cited by 9
Cancers colorectaux avec mutation V600E de BRAF : où en sommes-nous ?
Lièvre, A., de la Fouchardière, C., Samalin, E., Benoist, S., Phelip, J., André, T., & Lledo, G. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.04.017 · Cited by 9
Voutsadakis, I. A. (2022) · Medicina · doi:10.3390/medicina58101498 · Cited by 8
Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going
Sun, C., España, S., Bugés, C., Layos, L., Hierro, C., & Manzano, J. L. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.01.009 · Cited by 8
Alfonso, P. G., Lièvre, A., Loupakis, F., Tadmouri, A., Khan, S., Barcena, L., & Stintzing, S. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103646 · Cited by 8
Cell line models for drug discovery in PIK3CA-mutated colorectal cancers
Voutsadakis, I. A. (2022) · Medical Oncology · doi:10.1007/s12032-022-01695-y · Cited by 8
Mondaca, S., Lacouture, M. E., Hersch, J., & Yaeger, R. D. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00088 · Cited by 8
Self-citationFirst‐line therapy for metastatic colorectal cancer: Current perspectives and future directions
Burge, M., Price, T. J., & Karapetis, C. S. (2019) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13119 · Cited by 8
Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer
Rubio-Cuesta, B., Carretero-Puche, C., Llamas, P., Sarmentero, J., Gil-Calderon, B., Lens-Pardo, A., Antón-Pascual, B., Rubio-González, E., Cámara-Jurado, M., Salamanca, J., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03058-6 · Cited by 7
De-regulation of aurora kinases by oncogenic HPV; implications in cancer development and treatment
Oladipo, K. H., & Parish, J. L. (2025) · Tumour Virus Research · doi:10.1016/j.tvr.2025.200314 · Cited by 7
Lim, S. H., Lee, S.-Y., Hong, J. Y., Lee, J., & Kim, S. T. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-20 · Cited by 8
Scaini, M. C., Piccin, L., Bassani, D., Scapinello, A., Pellegrini, S., Poggiana, C., Catoni, C., Tonello, D., Pigozzo, J., Dall’Olmo, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512285 · Cited by 7
Advances in the therapy of BRAFV600E metastatic colorectal cancer
Jin, Z., & Sinicrope, F. A. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1661778 · Cited by 6
Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies
Ros, J., Gonzalez, N. S., Salvà, F., Baraibar, I., Alonso, G., Tabernero, J. M., & Élez, E. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2040016 · Cited by 6
Self-citationFrom PIK3CA Mutations to Rational PI3K Inhibition for the Treatment of Colorectal Cancer
Voutsadakis, I. A. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-025-00815-4 · Cited by 5
Ansab, M., Rath, S., Araib, E., Ishaque, G., Ramzan, N. U. H., Qasim, S. A., & Şahin, İ. H. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104947 · Cited by 5
Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics
Grochot, R. M., Bartolini, M., Algaze, S. D., Reimann, P., Winder, T., Lenz, H., & Fontana, E. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-516576 · Cited by 5
Self-citationMorris, V. K. (2019) · Current Colorectal Cancer Reports · doi:10.1007/s11888-019-00429-z · Cited by 6
New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients
Ruffinelli, J. C., Vivas, C. S., Pamplona, R. S., & Moreno, V. R. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1826305 · Cited by 4
BRAF Inhibitors in BRAF-Mutated Colorectal Cancer: A Systematic Review
Aiman, W., Ali, M., Jumean, S., Asfeen, U. Z., García, J., Quirem, M., Ahmad, A., Rayad, M., Alkhlaifat, O., Omour, B. I. A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010113 · Cited by 5
Antoniotti, C., Moretto, R., Rossini, D., Masi, G., Falcone, A., & Cremolini, C. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102135 · Cited by 6
Morris, V. K., Kee, B. K., Overman, M. J., Dasari, A. N., Raghav, K. P. S., Johnson, B., Parseghian, C. M., Wolff, R. A., Garg, N., Eng, C., et al. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-471 · Cited by 5
Damato, A., Rotolo, M., Caputo, F., Borghi, E., Iachetta, F., & Pinto, C. (2022) · Life · doi:10.3390/life12081137 · Cited by 5
Car, I., Dittmann, A., Vasieva, O., Bočkor, L., Grbčić, P., Piteša, N., Klobučar, M., Pavelić, S. K., & Sedić, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612906 · Cited by 4
Current status and perspectives of genetic testing in gastrointestinal cancer (Review)
Matsuoka, T., & Yashiro, M. (2023) · Oncology Letters · doi:10.3892/ol.2023.14155 · Cited by 5
Guo, H., Miao, L., & Yu, C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177219 · Cited by 4
Antoniotti, C., Ongaro, E., Falcone, A., & Cremolini, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082298 · Cited by 4
Deshmukh, R., Verma, S., Yaduwanshi, P. S., Dubey, A., & Kumari, M. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096333058241114064802 · Cited by 5
Treating BRAFV600E metastatic colorectal patients in 2019: a BEACON of hope?
de la Fouchardière, C. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.08.110 · Cited by 2
Kim, J. E., Kim, J., Kim, S., Cho, H., Ryu, Y., Hong, Y. S., Kim, S. Y., & Kim, T. W. (2022) · Cancers · doi:10.3390/cancers14102383 · Cited by 3
Anticancer Target Combinations: Network- Informed Signaling-Based Approach to DiscoveryPreprint
Yavuz, B. R., Jang, H., & Nussinov, R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.11.617918 · Cited by 3
Therapeutic Intervention of Signaling Pathways in Colorectal Cancer
Chandra, V., Tiwari, A., Singh, R. P., & Desai, K. V. (2022) · Springer eBooks · doi:10.1007/978-3-030-72702-4_8 · Cited by 2
Drug–drug synthetic lethality to combat cancer: From bench to bedside
Chen, Y., Wu, Y., Zheng, J., Bernards, R., & Jin, H. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1269 · Cited by 2
Endoplasmic Reticulum Stress and Emerging Therapeutic Targets in Cancer
Yeap, J. W., & Tan, M. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_271-1 · Cited by 2
Kasai, S., Sato, E., Sakaguchi, C., & Sasaki, Y. (2024) · Internal Medicine · doi:10.2169/internalmedicine.2925-23 · Cited by 1
Solé-Blanch, C., España, S., de la Puente-Noël, A., Marín-Béjar, O., Manzano, J. L., & Martínez‐Cardús, A. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189503 · Cited by 1
Metadata
- Authors
- van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., Faris, J. E., Eskens, F. A. L. M., Sharma, S., Yaeger, R., Lenz, H.-J., Wainberg, Z. A., Avsar, E., Chatterjee, A., Jaeger, S., Tan, E., Maharry, K., Demuth, T., & Schellens, J. H. M.
- Affiliations
- 1The Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Universitat Autònoma de Barcelona (ES)
- 2Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
- Sarah Cannon (US)
- Princess Margaret Cancer Centre (CA)
- 5West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany, and German Cancer Consortium (DKTK), partner site University Hospital Essen, Essen, Germany.
- 6National Cancer Center Hospital East, Chiba, Japan.
- Institut Claudius Regaud (FR)
- National Cancer Centre Japan (JP)
- University Medical Center Utrecht (NL)
- Massachusetts General Hospital (US)
- Erasmus MC Cancer Institute (NL)
- University of Utah (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Southern California (US)
- UCLA Medical Center (US)
- 16Novartis Pharmaceutical Corporation, East Hanover, New Jersey.
- Novartis (Switzerland) (CH)
- Array BioPharma (United States) (US)
- Utrecht University (NL)
- Corresponding author
- Schellens, Jan H.M.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2017-06-01
- Volume
- 7
- Issue
- 6
- Pages
- 610-619
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5546207
- OpenAlex
- W2598954950
- Semantic Scholar
- f08561cbc6f4d52344eed025d3e11163cdf45bff
- Cited by
- 232
- References
- 46
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 16 · 2023: 29 · 2022: 38 · 2021: 27 · 2020: 35 · 2019: 30 · 2018: 23 · 2017: 10
- FWCI
- 11.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Funders
- German Cancer Consortium (110534)
- EU Seventh Framework Programme (259015)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- encorafenib, cetuximab, alpelisib, BRAF V600E mutation, metastatic colorectal cancer, Raf kinase inhibitor, EGFR inhibition, PI3Kα inhibitor, MAPK signaling, combination therapy, dose-limiting toxicity, maximum tolerated dose, triple therapy
- MeSH terms
- Cetuximab, Phosphoinositide-3 Kinase Inhibitors, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carbamates, Female, Humans, Male, Middle Aged, Mutation, Sulfonamides, Thiazoles, Colorectal Neoplasms, Disease-Free Survival, Maximum Tolerated Dose, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
